OtherApr 7, 2026, 04:26 PM
ANI Pharmaceuticals Appoints Ernst & Young as New Independent Auditor, Replacing EisnerAmper
AI Summary
ANI Pharmaceuticals, Inc. (ANIP) announced a change in its independent registered public accounting firm, effective April 1, 2026. The company dismissed EisnerAmper LLP and simultaneously appointed Ernst & Young LLP (EY) to serve in this capacity. This transition appears to be a routine change, as the company explicitly stated there were no disagreements or reportable events with EisnerAmper concerning accounting principles, financial disclosures, or auditing scope for the fiscal years ended December 31, 2025, and 2024. The Audit and Finance Committee of the Board of Directors approved both the dismissal and the appointment.
Key Highlights
- ANI Pharmaceuticals, Inc. dismissed EisnerAmper LLP as its independent registered public accounting firm, effective April 1, 2026.
- The Audit and Finance Committee approved the appointment of Ernst & Young LLP (EY) as the Company’s new independent registered public accounting firm, also effective April 1, 2026.
- EisnerAmper's reports on the Company’s financial statements for the fiscal years ended December 31, 2025, and 2024, did not contain any adverse opinions, disclaimers, or qualifications.
- There were no disagreements or "reportable events" with EisnerAmper during the fiscal years 2025, 2024, and through April 1, 2026.
Price Impact
More from ANIP